Low-dose anthracyclines may block HIF-1 and stop tumor growth.
Hede
Karyn
K
D020533:Angiogenesis Inhibitors / Q000008:administration & dosage / Q000494:pharmacology*; D000818:Animals; D018943:Anthracyclines / Q000008:administration & dosage / Q000494:pharmacology*; D000903:Antibiotics, Antineoplastic / Q000008:administration & dosage / Q000494:pharmacology*; D001943:Breast Neoplasms / Q000188:drug therapy; D015687:Cell Hypoxia / Q000187:drug effects / Q000528:radiation effects; D004077:Digoxin / Q000008:administration & dosage / Q000494:pharmacology*; D005260:Female; D006801:Humans; D051793:Hypoxia-Inducible Factor 1 / Q000187:drug effects* / Q000378:metabolism; D008175:Lung Neoplasms / Q000188:drug therapy; D008297:Male; D009369:Neoplasms / Q000098:blood supply / Q000188:drug therapy* / Q000378:metabolism; D009389:Neovascularization, Pathologic / Q000517:prevention & control*; D015398:Signal Transduction / Q000187:drug effects; D014183:Transplantation, Heterologous
D020533:Angiogenesis Inhibitors; D018943:Anthracyclines; D000903:Antibiotics, Antineoplastic; D051793:Hypoxia-Inducible Factor 1; D004077:Digoxin